Inuvo to Present at Next Week’s Ladenburg Conference, Shares Stay Put
Inuvo, Inc. (NYSE: INUV) shares were fairly flat Wednesday, as the leading provider of artificial intelligence AdTech solutions, announced today that it will be participating in the Ladenburg Thalmann Innovation EXPO25, to be held on May 21, at Convene in New York.CEO Richard Howe is scheduled to present on Wednesday, May 21 at 11:30 a.m. Eastern Daylight Time. Management will also be available for one-on-one meetings with investors throughout the conference.The Ladenburg Thalmann Innovation EXPO25 is a premier event bringing together a diverse group of innovative companies and institutional investors for a full day of presentations, one-on-one meetings, and networking opportunities. The conference will feature approximately 50 technology companies that leverage AI in innovative and breakthrough ways. Participating companies will present their business strategies and innovations through three dedicated presentation tracks and demonstrate their products live in the “Ladenburg Expo format.”Inuvo, claims to be a market leader in Artificial Intelligence built for advertising. Its IntentKey AI solution is a first-of-its-kind proprietary and patented technology capable of identifying and actioning to the reasons why consumers are interested in products, services, or brands, not who those consumers are.INUV shares edged up 0.02 cents to 42 cents.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


